Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025
Rhea-AI Summary
Cidara Therapeutics (CDTX), a biotechnology company specializing in drug-Fc conjugate immunotherapies through its proprietary Cloudbreak® platform, has scheduled its first quarter 2025 financial results announcement for May 8, 2025. The results will be released after U.S. market close, followed by a conference call and webcast at 5:00 PM Eastern Time to discuss financial performance and provide operational updates.
Positive
- None.
Negative
- None.
News Market Reaction – CDTX
On the day this news was published, CDTX declined 1.92%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, May 8, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information
| Date: | Thursday, May 8, 2025 |
| Time: | 5:00 PM Eastern Time |
| United States: | 1-800-717-1738 |
| International: | 1-646-307-1865 |
| Conference ID: | 90743 |
| Webcast: | Link |
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When will Cidara Therapeutics (CDTX) release Q1 2025 earnings?
How can investors join Cidara Therapeutics (CDTX) Q1 2025 earnings call?
What is Cidara Therapeutics' (CDTX) main technology platform?
Is this Cidara Therapeutics' (CDTX) first quarterly earnings call?
